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Abstract
Compared to women of European ancestry (EA), those of African ancestry (AA) are more likely 
to develop estrogen receptor (ER) negative breast cancer, although the mechanisms have not been 
elucidated. We tested the associations between breast cancer risk and a targeted set of 20 genes 
known to be involved in estrogen synthesis, metabolism and response and potential gene-
environment interactions using data and samples from 1307 EA (658 cases) and 1365 AA (621 
cases) participants from the Women’s Circle of Health Study (WCHS). Multivariable logistic 
regression found evidence of associations with single nucleotide polymorphisms (SNPs) in the 
ESR1 gene in EA women (rs1801132, OR=1.47, 95%CI=1.20–1.80, p=0.0002; rs2046210, 
OR=1.24, 95%CI=1.04–1.47, p=0.02; and rs3020314, OR=1.43, 95%CI=1.19–1.70, p=0.00009); 
but not in AA women. The only other gene associated with breast cancer risk was CYP1A2 in AA 
women (rs2470893, OR=1.42, 95%CI=1.00–2.02, p=0.05), but not in EA women. When stratified 
by ER status, ESR1 rs1801132, rs2046210 and rs3020314 showed stronger associations in ER 
positive than in ER negative breast cancer in only EA women. Associations with the ESR1 SNPs 
in EA women also appeared to be stronger with longer endogenous estrogen exposure or hormonal 
replacement therapy (HRT) use. Our results indicate that there may be differential genetic 
influences on breast cancer risk in EA compared to AA women and these differences may be 
modified by tumor subtype and estrogen exposures. Future studies with a larger sample size may 
determine the full contribution of estrogen-related genes to racial/ethnic differences of breast 
cancer.
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Introduction
Breast cancer is a heterogeneous disease. Distribution of tumor characteristics, such as the 
expression of estrogen receptor (ER), varies by age and ethnic/racial background 
(Ambrosone, et al. 2014a; Millikan, et al. 2008). Compared to American women of 
European ancestry (EA), those of African ancestry (AA) are more likely to be diagnosed 
with breast cancer before age 50, and to have tumors with more aggressive features, such as 
ER negative status (Amend, et al. 2006). These tumors do not respond to anti-estrogen 
therapy and typically have poorer clinical outcomes (Chlebowski, et al. 2005). Although the 
mechanisms underlying such disparities are not yet known, it has been reported that breast 
cancer racial differences persist after adjustment for socioeconomic status and lifestyle 
factors (Amend et al. 2006). A high proportion of ER negative breast cancer has also been 
shown in indigenous African women (Fregene and Newman 2005; Huo, et al. 2009), 
suggesting that genetic factors related to African ancestry may, in part, account for the 
higher proportion of more aggressive breast cancer in AA women. Because populations of 
African ancestry typically exhibit shorter linkage disequilibrium (LD) blocks across the 
genome compared to populations of European ancestry (Haiman and Stram 2010; Hinch, et 
al. 2011), genetic studies in AAs may not only illustrate mechanisms underlying racial 
disparities of breast cancer, but also facilitate the identification of casual genetic loci 
(O’Brien, et al. 2014).
High levels of circulating estrogens and their metabolites, which have recently been shown 
to correlate with those in the local breast tissue (Loud, et al. 2014), are associated with 
increased risk of breast cancer among postmenopausal women (Fuhrman, et al. 2012; Key, 
et al. 2002), likely due to the dual effects of estrogens to stimulate cell proliferation and 
gene expression through binding with estrogen receptors and to cause DNA damage via 
mutagenic estrogen metabolites such as 2-OH and 4-OH catechol estrogens (Liehr 1997; 
Pike, et al. 1993). Because AA women have elevated serum concentrations of estrogens 
(Pinheiro, et al. 2005; Setiawan, et al. 2006), as well as different profiles of hormone-related 
factors, such as age of menopause, age of menarche, breast feeding, parity and HRT use, as 
compared to EA women (Brett and Madans 1997; Millikan et al. 2008), it is postulated that 
breast cancer racial disparities may be attributed, in part, to estrogens and related hormonal 
factor. This postulation is supported in several recent studies, including those from our 
group (Ambrosone et al. 2014a; Ambrosone, et al. 2014b; Millikan et al. 2008; Palmer, et al. 
2011).
Genetic variations involved in estrogen biosynthesis, metabolism and response pathways 
may contribute to a woman’s lifetime estrogen exposure, and thus influence the risk of 
breast cancer (Thompson and Ambrosone 2000). A number of candidate association studies 
have examined variants in estrogen-related genes with breast cancer mostly in EAs, while 
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similar studies in AAs are still sparse (Kato, et al. 2009; Rebbeck, et al. 2007; Taioli, et al. 
1995; Van Emburgh, et al. 2008). A SNP in estrogen receptor alpha (ESR1) gene, 
rs2046210, was associated with breast cancer risk in genome-wide association studies 
(GWAS) first in an Asian population (Zheng, et al. 2009b) and subsequently in populations 
of the European descendent (Michailidou, et al. 2013). However, it remains unclear whether 
ESR1 rs2046210 is also associated with risk of breast cancer in AAs (Hutter, et al. 2011; 
Long, et al. 2013; O’Brien et al. 2014). Furthermore, it is possible that gene-environment 
interactions within the hormone-related pathways may contribute to racial disparities of 
breast cancer; nevertheless, even fewer studies have examined these interactions in AAs 
(Reding, et al. 2012).
In a large case-control study with a similar number of AA and EA women, we 
systematically examined associations between selected genetic variants in estrogen 
biosynthesis, metabolism and response pathways and risk of breast cancer, overall and by 
ER status, and their potential interactions with estrogen-related factors.
Materials and Methods
Study Participants
The Women’s Circle of Health Study (WCHS) is a case-control study designed to evaluate 
risk factors for aggressive breast cancer in AA women. The study was conducted in the 
metropolitan area of New York City between 2003 and 2008 and in New Jersey (NJ) 
between 2003 and 2012, and has been previously described in detail (Ambrosone, et al. 
2009; Yao, et al. 2012). Eligible participants included English-speaking AA and EA women 
age 20 to 75 years, diagnosed with incident, primary, histologically confirmed breast cancer 
and had no previous history of cancer other than non-melanoma skin cancer. Controls 
without a history of any cancer diagnosis other than non-melanoma skin cancer were 
identified by random-digit dialing (RDD) and matched to cases on race and 5-year age 
group. Enrollment of AA controls in NJ was supplemented with community-based 
recruitment, as a combination of RDD and community controls was shown to be more 
representative of the general population in NJ (Bandera, et al. 2013). Controls were recruited 
and interviewed using the same standardized method and during the same time period as the 
cases at both sites.
Overall, the participation rate for those who were contacted and eligible was 79% and 49% 
in EA cases and controls, respectively, and 79% and 48% in AA cases and controls, 
respectively. A total of 658 EA cases, 715 EA controls, 621 AA cases, and 744 AA controls 
from the WCHS were available at the time of genotyping and thus included in the study. 
This study was approved by the Institutional Review Boards at Roswell Park Cancer 
Institute (RPCI), Rutgers Cancer Institute of New Jersey (CINJ), the Icahn School of 
Medicine at Mount Sinai, and participating hospitals in New York City, functioning 
according to the 3rd edition of the Guidelines on the Practice of Ethical Committees in 
Medical Research issued by the Royal College of Physicians of London.
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In-depth in-person interviews were conducted to collect information on a variety of factors 
known or suspected to affect breast cancer risk, including demographics, reproductive 
factors, medical history, family history of cancer, lifestyle factors, as well as biospecimens. 
Anthropometric measures were also collected during the interview. Pathology reports were 
obtained from hospitals at which patients were diagnosed. Information on ER status was 
available for 468 EA cases (82 ER negative) and 473 AA cases (150 ER negative). Informed 
consent, including permission to obtain pathology data and tumor tissue blocks, was 
obtained from each participant.
Sample Collection and Genotyping
Initially, blood samples were collected from study participants. We later transitioned to non-
invasive collection of saliva for DNA extraction. Genomic DNA was extracted in batches 
from whole blood using the FlexiGene DNA protocol (Qiagen Inc, Valencia, CA, US) and 
from saliva using the Oragene protocol (DNA Genotek Inc., Ottawa, ON, Canada). Quality 
and quantity of purified DNA were evaluated using Nanodrop UV-spectrometer (Thermo 
Fisher Scientific Inc., Wilmington, DE, US) and PicoGreen–based fluorometric assays 
(Invitrogen Inc., Carslbad, CA, US). DNA samples were stored at −80°C until analysis.
We included in our analysis all major genes involved in the estrogen biosynthesis, 
metabolism and response pathways, including cytochrome-dependent monooxygenase 
(CYP) genes, hydroxysteroid dehydrogenase (HSD) genes, Catechol-O-methyltransferase 
(COMT), UDP-glucuronosyltransferase (UGT) genes, and also estrogen receptor (ESR) 
genes (Suppl. Figure 1) (Germain 2011; Liang and Shang 2013; Yager and Davidson 2006). 
We then surveyed the Human Genome Epidemiology (HuGE) Navigator for the selected 
genes to identify SNPs within these genes that were previously associated with risk of any 
cancer or cancer outcome, with a focus on SNPs that were previously shown to be functional 
(Yu, et al. 2008). Genomic DNA was plated and genotyped at the Genomics Core Facility at 
RPCI using MassARRAY technology and iPLEX Gold Assay (Sequenom Inc., San Diego, 
CA, US). Five percent duplicates and two sets of in-house trio samples of European and 
African ancestry were included for quality control purposes. The concordance among blind 
duplicate pairs was >99.9%. The average successful genotyping rate for each sample and 
SNP was 95.9%. Samples or SNPs with call rate <90% were excluded, as were 
monomorphic SNPs or SNPs with an MAF<5% in both AA and EA controls. For each SNP, 
Hardy-Weinberg equilibrium was assessed among controls. SNPs deviating from Hardy-
Weinberg equilibrium (HWE) in both EA and AA controls were excluded. Clustering plots 
of SNPs that were significant in the statistical analysis were manually re-inspected post-hoc 
to ensure that the calls for genotype of each sample were robust. We selected 62 SNPs for 
the assay design: 5 of them failed in the assay design and validation process, 3 were 
excluded due to low call rate, 3 were monomorphic or rare and excluded, and another 2 were 
excluded for violating HWE, leaving a total of 49 SNPs in 20 genes included in our analyses 
(Suppl. Table1). The major allele of each SNP in EA controls is defined as the reference 
allele and the minor allele as the coded allele. To account for the potential inaccuracy of 
self-reported race/ethnicity and to assess ancestry quantitatively, all DNA samples were also 
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genotyped for a panel of 100 ancestry informative markers (AIMs) (Ruiz-Narvaez, et al. 
2011) using the Illumina GoldenGate targeted multiplex assay.
Statistical Analysis
All analyses were conducted using SAS 9.4 (SAS Institute, Cary CA) separately for EA and 
AA women, according to self-reported race. Descriptive variables were compared between 
cases and controls using Chi-square tests for categorical variables and Wilcoxon rank-sum 
test for continuous variables. Proportions of European and African ancestry in individual EA 
and AA woman were estimated quantitatively based on AIM genotypes using the Bayesian 
Markov Chain Monte Carlo clustering algorithm implemented in STRUCTURE 2.3 
(Pritchard, et al. 2000). Since the sum of two ancestral proportions in each individual is 
always one, we used only the proportion of European Ancestry in all analyses. Genotype 
frequencies of each SNP were compared between EA and AA controls using Chi-square test 
or Fisher’s Exact test where appropriate. To compare allele frequencies obtained from our 
study to those previously reported, frequencies for Caucasians (CEU), African Americans of 
the American Southwest (ASW) and Yoruban in Ibadan, Nigeria (YRI) were obtained from 
HapMap release #28 (phase 1, 2 and 3 merged).
Odds ratios (ORs) and 95% confidence intervals (CIs) for each SNP were derived from 
multivariable logistic regression models, assuming codominant or additive genetic models, 
with adjustment for known risk factors of breast cancer, overall and by ER subtypes or 
estrogen exposure status (Althuis, et al. 2004; Ambrosone et al. 2014b; Gordon 1995; 
Hwang, et al. 2005; Krieger, et al. 2008): including age at diagnosis, education, family 
history of breast cancer, history of benign breast disease, menopausal status, number of full-
term pregnancies, breast feeding, hormone replacement therapy (HRT), body mass index 
(BMI), proportion of European ancestry and “estrogen months”. The variable “estrogen 
months”, reflecting total months of exposure to endogenous estrogen, is defined as 
following: “months between age at enrollment and age at menarche” (“months between age 
of menopause and age at menarche” in postmenopausal women) minus “months of 
pregnancy”, then minus “months of breastfeeding”. P for linear trend was calculated by 
coding SNPs as 0, 1, 2 and testing whether there was a linear dose-response effect of the 
variant allele as an ordinal variable. P values were adjusted for multiple comparisons using a 




Participant characteristics are shown in Table 1. Among EA women, cases were 
significantly more likely than controls to have a family history of breast cancer in a first-
degree relative, less likely to have breastfed or to have attended college or graduate school. 
AA cases were less highly educated than controls, although differences were not statistically 
significant. Among both EA and AA women, cases were more likely to have a history of 
benign breast disease and to have longer exposure to endogenous estrogen before 
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menopause. Cases were also slightly older than controls but within 5-year age range in both 
EA and AA women. Cases did not differ significantly from controls in body mass index 
(BMI), HRT use in postmenopausal women, or number of full-term pregnancy in either 
group.
Breast Cancer Risk in EA and AA Women
For 41 of the 49 SNPs analyzed (84%), genotype frequencies differed significantly between 
AA and EA controls (Supplementary Table 1, p < 0.05 after correction for multiple testing). 
Sixteen SNPs had ‘flipped’ minor alleles, where the minor allele among EA controls was the 
major allele among AA controls, and vice versa (Supplementary Table 1, rs2046210 and 
rs3020314 in Table 2 for example). Genotype frequencies obtained from the HapMap 
database for each ancestry were very similar to those in our study (data not shown). Because 
of the notable differences in allele distributions between EA and AA women, all analyses 
were stratified by self-reported race.
ORs and 95% CIs for associations between overall breast cancer risk and all 49 SNPs 
analyzed are shown in Supplementary Table 2. Significant associations in either EA or AA 
women with a p for trend < 0.05 before correction for multiple testing are shown in Table 2. 
We found different associations in EA and AA women. Three SNPs in the ESR1 gene, i.e. 
rs1801132, rs2046210 and rs3020314, were associated with an increased risk of breast 
cancer in EA women (Table 2, OR=1.47, 95% CI= 1.20–1.80, p=0.0002, pc=0.001; 
OR=1.24, 95% CI= 1.04–1.47, p=0.02; and OR=1.43, 95% CI= 1.19–1.70, p=0.00009, 
pc=0.0004; respectively). The three SNPs were not in linkage delirium (LD) with each other 
in the EA control subjects. In addition, SNP rs2470893 in CYP1A2 was the only one 
marginally associated with an increased breast cancer risk in AA women (Table 2, OR=1.42, 
95% CI= 1.00–2.02, p=0.05).
Risk for Breast Cancer by ER Status
As expected, ER negative breast cancer was more common among AA (31.7%) than among 
EA women (17.5%). We next examined whether the associations between estrogen-related 
genes and breast cancer risk by ER status also differ in EA and AA women. Number of 
subjects, ORs and 95% CIs of ER positive or ER negative breast cancer for all 49 SNPs are 
shown in Supplementary Table 3. Significant associations in either EA or AA women with a 
p for trend <0.05 before correction for multiple testing are shown in Table 3. All four 
significant SNPs identified in the overall analysis remained significant. The three SNPs in 
ESR1 gene, i.e. rs1801132, rs2046210 and rs3020314, were associated with an increased 
risk of both ER positive and ER negative breast cancer in EA women, although the OR 
estimates for ER negative breast cancer were slightly lower and only significant for 
rs3020314 (Table 3). SNP rs2470893 in CYP1A2 was primarily associated with an increased 
risk of ER positive breast cancer in AA women (Table 3). We also found three new 
associations: CYP17A1 rs12413409 was associated with an increased risk of ER negative 
breast cancer in EA women (Table 3, OR=1.92, 95% CI=1.15–3.21, p=0.01); HSD17B2 
rs4445895 was associated with a decreased risk of ER negative breast cancer in EA women 
(Table 3, OR=0.62, 95% CI=0.43–0.90, p=0.01), but an increased risk of ER positive breast 
cancer in AA women (Table 3, OR=1.24, 95% CI=1.01–1.52, p=0.04); UGT1A9 rs6714486 
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was marginally associated with a decreased risk of ER positive breast cancer in AA women 
(Table 3, OR=0.75, 95% CI=0.57–0.98, p=0.04).
Stratification by Estrogen Months and HRT Use
It is plausible that gene-environment interactions within estrogen-related pathways may also 
contribute to the ethnic/racial differences in breast cancer characteristics. We therefore 
stratified the data by length of lifetime exposure to endogenous estrogen (longer or shorter 
than 384 estrogen months - the median in both AA and EA controls) or usage of HRT (yes 
or no). Number of subjects, ORs and 95% CIs of ER positive or ER negative breast cancer 
for all 49 SNPs are shown in Supplementary Tables 4 & 5. Estrogen month and usage of 
HRT were not independently associated with breast cancer risk in either EA or AA women 
(data not shown). However, the three SNPs in the ESR1 gene, i.e. rs1801132, rs2046210 and 
rs3020314, were associated with an increased risk of breast cancer in EA women with 
longer estrogen exposure, with smaller effects in EA women with shorter estrogen exposure 
(Table 4). Similar results were found when using race-specific medians as cutoffs 
(Supplementary Table 6). When stratified by HRT status in postmenopausal women, 
rs1801132 and rs3020314 in ESR1 were associated with an increased risk of breast cancers 
in EA women with HRT use (Table 5). ESR1 rs2046210, however, was associated with an 
increased risk of breast cancer only in non-user postmenopausal EA women (Table 5).
Discussion
Disparities in breast cancer biology are evident between EA and AA women and may be 
due, in part, to differences in genetic background (Quan, et al. 2014; Yao et al. 2012). 
Estrogens are synthesized from cholesterol through a cascade of enzymatic reactions (Tang, 
et al. 2011; Thompson and Ambrosone 2000). The parent estrogens, i.e. estrone and 
estradiol, can be irreversibly hydroxylated at the 2, 4 and 16 positions of the steroid ring to 
produce estrogen metabolites that have different affinity for the estrogen receptors, which 
may lead to differential risk of breast cancer (Zhu, et al. 2006). Moreover, both parent 
estrogens and estrogen metabolites can be modified by a series of enzymes that influences 
their bioavailability to breast tissue (Raftogianis, et al. 2000). In this study, we 
systematically examined associations between genes involved in estrogen biosynthesis, 
metabolism and response pathways (Suppl. Figure 1) and overall breast cancer risk, as well 
as by ER status and by estrogen exposure, in EA and AA women.
The primary study findings revealed differences between EA and AA women in the genetic 
architecture of selected genes in estrogen biosynthesis, metabolism and response pathways. 
Among the 49 SNPs in 20 genes examined, the allele frequencies of 41 SNPs (84%) differed 
significantly between EA and AA controls (Supplementary Table 1). Subsequently, we 
found differential relationships between estrogen-related genes and breast cancer risk in EA 
and AA women, in overall analysis, ER subtype analyses, and stratified analyses by estrogen 
exposures.
We found strong associations between three SNPs in the ESR1 gene and overall breast 
cancer risk in only EA women. The human ESR1 gene has eight exons that span 300kb on 
chromosome 6q25.1 and encodes the alpha form of the estrogen receptor (ERα). The three 
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SNPs, i.e. rs1801132, rs2046210 and rs3020314, were not in linkage disequilibrium (LD) 
with each other. Rs1801132 is a synonymous SNP at codon 325, which may influence 
mRNA stability and translation efficiency (Li, et al. 2010; Sauna, et al. 2007). The G allele 
of rs1801132 was associated with a decreased risk of breast cancer in a meta-analysis of 
5649 cases and 6856 controls, the majority of whom were Hispanic and Caucasians (CG/GG 
vs CC, OR=0.92, 95% CI=0.85–0.99) (Li et al. 2010). Rs2046210 is a SNP located 
upstream of ESR1 that was reported to be associated with breast cancer risk in a three-stage 
genome-wide association study (GWAS) in Asians (AA vs GG, OR=1.59, 95% CI=1.40–
1.82) (Zheng et al. 2009b) and subsequently in the European population (Michailidou et al. 
2013). SNP rs3020314 tags a highly conserved region of ESR1 intron 4 and may change the 
ratio of two mRNA splice forms (Dunning, et al. 2009; Fuqua and Wolf 1995). The G allele 
of rs3020314 was associated with an increased risk of breast cancer in a recent GWAS 
(OR=1.05, 95% CI=1.02–1.09) (Dunning et al. 2009). We found associations between breast 
cancer risk and all three SNPs in the same directions as previous reports in EA women, but 
no associations in AA women (Table 2), even after stratifications by ER status or by 
estrogen exposure status (Tables 3, 4 & 5). Previously, efforts to evaluate breast cancer 
GWAS variants in AA women have failed to replicate most variants discovered in European 
and Asian populations, including ESR1 rs2046210 (Campa, et al. 2011; Chen, et al. 2011; 
Hutter et al. 2011; Long et al. 2013; Stacey, et al. 2010; Zheng, et al. 2009a). However, a 
recently study using a Bayesian Approach replicated the association between breast cancer 
risk and ESR1 rs2046210 in AA women but not EA women (Hutter et al. 2011; Long et al. 
2013; O’Brien et al. 2014). Future studies are required to understand the detailed function of 
this SNP in different populations.
Estrogens are metabolized by a number cytochrome P450 enzymes. Previously, CYP 
enzymes such as CYP1A1 and CYP1B1 have been associated with breast cancer risk among 
AA women (Kato et al. 2009; Reding et al. 2012). As far as we know, we are the first to 
report a positive association between the A allele of CYP1A2 rs2470893 and breast cancer 
risk, which was only observed in AA women (Table 2). CYP1A2 rs2470893 is located in the 
bidirectional promoter region of the CYP1A1-CYP1A2 locus on chromosome 15q24. In 
addition to estrogen, the CYP1A2 enzyme metabolizes many exogenous compounds such as 
caffeine, insulin, and blood lipids, and may have complex effects on the risk of breast cancer 
(Hong, et al. 2004).
The associations between estrogen-related genes and risk of breast cancers by ER status 
have not been widely investigated. Among the SNPs associated with overall breast cancer 
risk, ESR1 rs1801132, rs2046210 and rs3020314 were associated with an increased risk of 
both ER positive and ER negative breast cancer in EA women, with stronger effects on ER 
positive tumors (Table 3). Such results indicated a more general effect of ESR1 regarding 
ER status of breast cancer. Indeed, a recent genome-wide association study reported that 
ESR1 rs2046210 are associated with risk of ER negative and triple negative (TN) breast 
cancers (Purrington, et al. 2014). In our ER subtype analyses, we also identified three other 
associations that were not observed for overall risk (Table 3). CYP17A1 rs12413409 was 
with the strongest effect, associated with an almost two-fold increase in the risk of ER 
negative breast cancer in EA women (Table 3). CYP17 converts pregnenolone into 
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dehydroepiandrosterone and progesterone into 17α-hydroxyprogesterone, both are essential 
precursors of estrogens (Feigelson, et al. 1998). Previously, CYP17A1 have been associated 
with breast cancer risk among younger women (Bergman-Jungestrom, et al. 1999; Spurdle, 
et al. 2000) and among subgroup of cases with more advanced breast cancer (Feigelson, et 
al. 1997). However, other studies have found null association between breast cancer risk and 
CYP17A1 (Miyoshi and Noguchi 2003). The association between CYP17A1 rs12413409 and 
ER negative breast cancer in EA women detected in the current study warrants future 
validation (Table 3).
The origins of ER negative breast cancer have been under debate (Santen and Allred 2007). 
One hypothesis suggests that ER negative breast cancer evolves from ER negative precursor 
cells. This view is supported by the fact that tamoxifen prevents only ER positive breast 
cancer in women of high risk (Sims, et al. 2007). In addition, there is evidence that ER 
negative stem cells are essential for normal breast development and gives rise to more 
differentiated ER-positive progenitor cells (Asselin-Labat, et al. 2006). An alternative 
hypothesis suggests that there are multiple mechanisms for the development of ER negative 
breast cancer, including that many may rise from ER positive precursors. This concept is 
supported by the fact that increased estrogen exposure is associated with an increased 
incidence of all breast cancers and that the proportion of ER negative breast cancer increases 
along with time of tumor progression (Santen and Allred 2007). Our findings that SNPs in 
the ESR1 gene were associated with an increased risk of both ER positive and ER negative 
breast cancers in EA women (Table 3), may provide further information on this issue.
Genotype alone is an incomplete surrogate for gene functions, which may interacts with 
other endogenous or exogenous factors (Thompson and Ambrosone 2000). We further 
stratified our analyses by the length of endogenous estrogen exposure or usage of HRT. We 
found associations with the three ESR1 SNPs, which is plausible since the ESR1 gene 
encodes effector molecules for estrogen and their metabolites. The associations appeared to 
be more pronounced in women with longer estrogen months or with HRT use, with the 
exception for rs2046210 among HRT non-users, and were observed only among EA women 
(Table 4 and 5).
Our study has several strengths. We conducted in-person interviews to assure data accuracy. 
In-depth information on medical history, family history of cancer, hormone-related, and 
lifestyle factors were collected, allowing us to adjust for potential confounders. We included 
in the study a large number of cases and controls, both EA and AA, enabling us to stratify 
by ancestry group and address racial disparities. To account for the high levels of genetic 
diversity within self-reported race group, we also estimated the percentage of European 
ancestry (or African ancestry) using a set of AIMs (Ruiz-Narvaez et al. 2011). Data on ER 
status was available for a large proportion of cases, so we were able to identify SNPs 
specifically associated with ER positive or ER negative breast cancers.
We are aware that SNPs identified as related to breast cancer in our study may not be causal. 
It is possible that they are in LD with other SNPs that are in a causal pathway but were not 
tested. We showed all SNPs that were significant before correction for multiple comparisons 
because our primary goal was to identify promising and biologically relevant associations, 
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which may motivate future studies for replication and extension. P values adjusted for 
multiple comparisons were also provided in the tables. The response rates among EA and 
AA control subjects were relatively low (49% and 48.2%, respectively) in our study and 
could lead to potential selection bias. However, an approximately 50% response rate was not 
uncommon in population studies (Hartge 2006). ER status was missing for 190 cases 
(28.9%) among EA women and 148 cases (23.8%) among AA women in our study. The 
missing rate in our study is comparable or lower than in other similar studies (Long et al. 
2013; Palmer, et al. 2013). We are aware of potential impact of this substantial data missing 
on our analysis. It is possible that ER status may not be missing completely at random. 
Some studies have suggested ER status is more frequently missing among women of color 
or of lower socioeconomic status, likely due to inadequacies of medical care (Krieger N. et 
al, 2008). However, in our study, ER status was missing at a similar rate between EA and 
AA women; and there were no obvious differences in missing ER status crossing various 
levels of education among either EA or AA women in our study (data not shown). It is thus 
likely the missing is non-differential and would have limited impact on the analysis besides 
lowering statistical power.
In conclusion, the present study revealed genetic variants and potential gene-environment 
interactions within the estrogen biosynthesis, metabolism and response pathways associated 
with breast cancer risk in EA and AA women. The associations appeared to differ between 
EA and AA women, and this is true after stratification by ER status or estrogen exposure. 
Additional research is now warranted to validate these initial findings in a larger sample size 
and to assess their utility in predicting breast cancer risk or treatment response for anti-
estrogen prevention in women at high risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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